Zachary Reese, MD
Hematology & Oncology · St George, UTNPI 1871735340
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $555 of the $648 with a category attached, or 85.6%. 16 manufacturers reported payments, led by Globus Medical at 27.7% of the total. Reporting peaked in 2019 at $426 and has fallen 67.0% since, to $141 in 2025. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 29 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$180
- Merck$86
- Novo Nordisk$48
- Boston Scientific$45
- Inogen, Inc.$39
- AstraZeneca$34
- plus $216 from 10 others
Across 9 payments — averaging $30,727 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$277K
What the payments were for
- Food & beverage$55586%
- Education$9314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 2 | $180 |
| Merck | 5 | $86 |
| Novo Nordisk | 3 | $48 |
| Boston Scientific | 2 | $45 |
| Inogen, Inc. | 1 | $39 |
| AstraZeneca | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Amgen | 2 | $29 |
| Clovis Oncology, Inc. | 3 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Pfizer | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XLIF$163
How this compares
$648 in reported general payments places this provider in the 30th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $558,548 |
| ImbruvicaIbrutinib | 32 | $499,388 |
| XtandiEnzalutamide | 34 | $473,923 |
| CalquenceAcalabrutinib Maleate | 29 | $396,285 |
| JakafiRuxolitinib Phosphate | 17 | $283,733 |
| VenclextaVenetoclax | 30 | $222,149 |
| Abiraterone Acetate | 209 | $99,743 |
| InqoviDecitabine/Cedazuridine | 11 | $91,623 |
| Fondaparinux Sodium | 12 | $19,374 |
| EliquisApixaban | 25 | $14,653 |
| Anastrozole | 142 | $2,432 |
| Hydroxyurea | 38 | $1,154 |
| Prednisone | 211 | $1,123 |
| Ondansetron Hcl | 87 | $932 |
| Acyclovir | 79 | $758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $24 | $573,20159 claims |
| AstraZenecaCalquence | $34 | $396,28529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in St George
- Joseph TeSt George$29K
- Derrick HaslemSt George$3K
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Terence RhodesCedar City$147K
- Benjamin MaughanSalt Lake City$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.